Campbell & CO Investment Adviser LLC bought a new stake in Meridian Bioscience, Inc. (NASDAQ:VIVO) during the 3rd quarter, Holdings Channel reports. The fund bought 12,243 shares of the company’s stock, valued at approximately $208,000.
Several other large investors have also modified their holdings of VIVO. Deerfield Management Company L.P. Series C bought a new stake in shares of Meridian Bioscience during the second quarter worth approximately $38,731,000. FMR LLC raised its position in shares of Meridian Bioscience by 322.5% during the 2nd quarter. FMR LLC now owns 1,110,089 shares of the company’s stock valued at $25,854,000 after acquiring an additional 847,376 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of Meridian Bioscience by 974.8% in the 2nd quarter. Prudential Financial Inc. now owns 714,821 shares of the company’s stock valued at $16,649,000 after purchasing an additional 648,316 shares during the period. Vanguard Group Inc. lifted its stake in shares of Meridian Bioscience by 6.1% in the 2nd quarter. Vanguard Group Inc. now owns 4,562,111 shares of the company’s stock valued at $106,251,000 after purchasing an additional 262,340 shares during the period. Finally, Nuveen Asset Management LLC boosted its position in shares of Meridian Bioscience by 47.0% in the 1st quarter. Nuveen Asset Management LLC now owns 764,903 shares of the company’s stock worth $6,425,000 after purchasing an additional 244,478 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.
VIVO has been the topic of a number of recent analyst reports. BidaskClub upgraded Meridian Bioscience from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 8th. HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Meridian Bioscience in a research note on Friday, September 18th. Finally, ValuEngine upgraded Meridian Bioscience from a “strong sell” rating to a “sell” rating in a report on Friday, September 18th. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.25.
Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.31. Meridian Bioscience had a return on equity of 21.11% and a net margin of 18.22%. The company had revenue of $84.80 million during the quarter, compared to analysts’ expectations of $66.12 million. On average, equities analysts expect that Meridian Bioscience, Inc. will post 0.93 EPS for the current year.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Featured Story: How Do Mutual Funds Work?
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.